Adams Diversified Equity Fund’s Regeneron Pharmaceuticals REGN Stock Holding History

Adams Diversified Equity Fund’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-19,700	Closed	-$10.3M	–	106
2025 Q2	$10.3M	Hold	19,700	–	–	0.37%	83
2025 Q1	$12.5M	Sell	19,700 -2,000	-9%	-$1.38M	0.5%	70
2024 Q4	$15.5M	Hold	21,700	–	–	0.58%	58
2024 Q3	$22.8M	Sell	21,700 -10,600	-33%	-$11.8M	0.84%	37
2024 Q2	$33.9M	Hold	32,300	–	–	1.16%	16
2024 Q1	$31.1M	Hold	32,300	–	–	1.1%	23
2023 Q4	$28.4M	Hold	32,300	–	–	1.12%	31
2023 Q3	$26.6M	Buy	32,300 +12,300	+62%	+$9.67M	1.14%	27
2023 Q2	$14.4M	Sell	20,000 -13,500	-40%	-$10.4M	0.6%	70
2023 Q1	$27.5M	Hold	33,500	–	–	1.24%	20
2022 Q4	$24.2M	Buy	33,500 +2,900	+9%	+$2.14M	1.16%	23
2022 Q3	$21.1M	Hold	30,600	–	–	1.05%	28
2022 Q2	$18.1M	Sell	30,600 -14,400	-32%	-$9.36M	0.86%	44
2022 Q1	$31.4M	Buy	45,000 +14,900	+50%	+$9.43M	1.25%	23
2021 Q4	$19M	Hold	30,100	–	–	0.72%	53
2021 Q3	$18.2M	Buy	+30,100	New	+$18.7M	0.72%	57

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Adams Diversified Equity Fund's REGN Position: Q3 2025 in Review

Adams Diversified Equity Fund sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 19,700 shares — an estimated $10.3M sold.

Adams Diversified Equity Fund first reported a position in REGN in Q3 2021 and held it in 16 quarters. The position peaked at $33.9M in Q2 2024. 1,245 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

Adams Diversified Equity Fund reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Adams Diversified Equity Fund sold 19,700 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $10.3M.
Adams Diversified Equity Fund first reported a position in Regeneron Pharmaceuticals in Q3 2021 and held it in 16 quarters.
Adams Diversified Equity Fund's Regeneron Pharmaceuticals position peaked at $33.9M in Q2 2024.
1,245 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Adams Diversified Equity Fund's 13F filing for Q3 2025, filed 22 Oct 2025.